Valcycon®
Inside, regardless of food intake, with water.
Treatment of herpes zoster (Herpes zoster)
Adults:
The recommended dose is 1000 mg 3 times a day for 7 days.
Treatment of infections caused by HSV (Herpes simplex)
Adults:
The recommended dose for treatment of an episode is 500 mg 2 times a day for 5 days.
In more severe cases of the onset of the disease, treatment should begin as early as possible, and its duration can be increased from 5 to 10 days. In case of relapse, treatment should continue for 3 or 5 days. For recurrent HSV, it is ideal to prescribe valacyclovir in the prodromal period or immediately after the first symptoms of the disease appear.
As an alternative for the treatment of labial herpes, the administration of valacyclovir at a dose of 2 g 2 times a day is effective. The second dose should be taken approximately 12 hours (but not earlier than 6 hours) after the first dose. When using this dosage regimen, the duration of treatment is 1 day. Therapy should be started when the earliest symptoms of herpes labialis appear: tingling, itching and/or burning.
Prevention (suppression) of recurrent infections caused by HSV
Adults:
In patients with preserved immunity, the recommended dose is 500 mg 1 time per day.
In patients with immunodeficiency, the recommended dose is 500 mg 2 times a day.
Prevention of transmission of genital herpes to a healthy partner
For infected immunocompetent individuals with relapses no more than 9 times a year, the recommended dose of valacyclovir is 500 mg once a day for a year or more, daily.
There are no data on infection prevention in other patient populations.
Prevention of cytomegalovirus (CMV) infection after transplantation
Adults and teenagers aged 12 years and older:
The recommended dose is 2 g 4 times a day, prescribed as early as possible after transplantation. The dose should be reduced depending on creatinine clearance (CC). The duration of treatment is 90 days, but in high-risk patients the course of treatment can be extended.
Special patient groups
Patients with impaired renal function:
- treatment of herpes zoster and infections caused by HSV, prevention (suppression) of relapses of infection caused by HSV, prevention of transmission of genital herpes to a healthy partner
It is recommended to reduce the dose of valacyclovir in patients with a significant decrease in renal function (see dosage regimen in Table 1). Adequate hydration should be maintained in such patients.
There is no experience with the use of valacyclovir in children with CC values less than 50 ml/min/1.73 m2.
Table 1
| Indications | CC, ml/min | Valacyclovir dose |
| Herpes zoster | 15-30 | 1 g 2 times a day |
| less than 15 | 1 g 1 time per day | |
| Treatment of infection caused by HSV (according to the regimen of 500 mg 2 times a day) | less than 15 | 500 mg 1 time per day |
| Treatment of labial herpes (according to the regimen of 2 g 2 times a day for one day) | 31-49 | 1 g twice a day |
| 15-30 | 500 mg twice a day | |
| less than 15 | 500 mg once | |
| Prevention (suppression) of recurrent infections caused by HSV: - patients with normal immunity - patients with reduced immunity – reducing the risk of transmission of genital herpes | ||
| less than 15 | 250 mg 1 time per day | |
| less than 15 | 500 mg 1 time per day | |
| less than 15 | 250 mg 1 time per day |
For patients on hemodialysis, it is recommended to use valacyclovir immediately after the end of the hemodialysis session at the same dose as in patients with CC less than 15 ml/min.
— prevention of cytomegalovirus (CMV) infection after transplantation
The regimen for valaciclovir in patients with impaired renal function should be established in accordance with Table 2.
table 2
| CC, ml/min | Valacyclovir dose |
| 75 or more | 2 g 4 times a day |
| from 50 to less than 75 | 1.5 g 4 times a day |
| from 25 to less than 50 | 1.5 g 3 times a day |
| from 10 to less than 25 | 1.5 g 2 times a day |
| less than 10 or hemodialysis* | 1.5 g 1 time per day |
* In patients undergoing hemodialysis, valacyclovir should be prescribed after the end of the hemodialysis session.
It is necessary to determine QC frequently, especially during periods when renal function changes rapidly, for example, immediately after transplantation or engraftment, and the dose of valacyclovir is adjusted in accordance with QC values.
Patients with liver dysfunction
In adult patients with mild to moderate hepatic impairment with preserved synthetic function, no dose adjustment of valacyclovir is required.
Pharmacokinetic data in adult patients with severely impaired liver function (decompensated cirrhosis), impaired synthetic liver function and the presence of portacaval anastomoses also do not indicate the need to adjust the dose of valacyclovir, however, clinical experience with this pathology is limited.
Children under 12 years of age
There is no data on the use of Valcicon® in children.
Elderly patients
No dose adjustment is required, except in patients with significant renal impairment. It is necessary to maintain adequate water and electrolyte balance.
Valcicon, 10 pcs., 500 mg, film-coated tablets
Inside,
regardless of food intake, washed down with water.
Adults
Treatment of herpes zoster (Herpes zoster):
The recommended dose is 1000 mg 3 times a day for 7 days.
Treatment of infections caused by HSV:
The recommended dose for treatment of an episode is 500 mg 2 times a day for 5 days. In more severe cases of the onset of the disease, treatment should begin as early as possible, and its duration can be increased from 5 to 10 days. In case of relapse, treatment should continue for 3 or 5 days. For recurrent HSV, it is ideal to prescribe valacyclovir in the prodromal period or immediately after the first symptoms of the disease appear.
As an alternative for the treatment of labial herpes, the administration of valacyclovir at a dose of 2 g 2 times a day is effective. The second dose should be taken approximately 12 hours (but not earlier than 6 hours) after taking the first dose. When using this dosage regimen, the duration of treatment is 1 day. Therapy should be started when the earliest symptoms of herpes labialis (ie, tingling, itching, burning) appear.
Prevention (suppression) of recurrent infections caused by HSV:
in patients with preserved immunity, the recommended dose is 500 mg 1 time per day. In patients with immunodeficiency, the recommended dose is 500 mg 2 times a day.
Prevention of transmission of genital herpes to a healthy partner:
For infected immunocompetent individuals with relapses no more than 9 times a year, the recommended dose of valacyclovir is 500 mg once a day for a year or more every day.
There are no data on infection prevention in other patient populations.
Adults and children 12 years and older
Prevention of CMV infection after transplantation:
The recommended dose is 2 g 4 times a day, prescribed as soon as possible after transplantation. The dose should be reduced depending on creatinine clearance. The duration of the course is 90 days, but in patients at high risk, the course of treatment can be extended.
Special patient groups
Renal dysfunction:
- treatment of herpes zoster and infections caused by HSV, prevention (suppression) of relapses of infection caused by HSV, prevention of transmission of genital herpes to a healthy partner.
It is recommended to reduce the dose of valacyclovir in patients with a significant decrease in renal function (see dosage regimen in Table 1). Adequate hydration should be maintained in such patients.
There is no experience with the use of valacyclovir in children with creatinine Cl values less than 50 ml/min/1.73 m2.
Table 1
| Indications | Creatinine Cl, ml/min | Valacyclovir dose |
| Shingles ( Herpes Zoster ) | 15–30 | 1 g 2 times a day |
| less than 15 | 1 g 1 time per day | |
| Treatment of infection caused by HSV (according to the regimen of 500 mg 2 times a day) | less than 15 | 500 mg 1 time per day |
| Treatment of labial herpes (according to the regimen of 2 g 2 times a day for 1 day) | 31–49 | 1 g 2 times a day |
| 15–30 | 500 mg 2 times a day | |
| less than 15 | 500 mg 1 time per day | |
| Prevention (suppression) of recurrent infections caused by HSV: | ||
| - patients with normal immunity | less than 15 | 250 mg 1 time per day |
| - patients with reduced immunity | less than 15 | 500 mg 1 time per day |
| – reducing the risk of transmission of genital herpes | less than 15 | 250 mg 1 time per day |
For patients on hemodialysis, it is recommended to use valacyclovir immediately after the end of the hemodialysis session at the same dose as in patients with creatinine Cl less than 15 ml/min.
— prevention of CMV infection after transplantation.
The regimen for valaciclovir in patients with impaired renal function should be established in accordance with Table 2.
table 2
| Creatinine Cl, ml/min | Valacyclovir dose |
| ≥75 | 2 g 4 times a day |
| from ≥50 to <75 | 1.5 g 4 times a day |
| from ≥25 to <50 | 1.5 g 3 times a day |
| from ≥10 to <25 | 1.5 g 2 times a day |
| <10 or hemodialysis* | 1.5 g 1 time per day |
* In patients undergoing hemodialysis, valacyclovir should be prescribed after a hemodialysis session.
Creatinine clearance should be determined frequently, especially during periods when renal function is rapidly changing, such as immediately after transplantation or engraftment, and the dose of valacyclovir should be adjusted according to creatinine clearance.
Liver dysfunction.
In adult patients with mild to moderate hepatic impairment with preserved synthetic function, no dosage adjustment of valacyclovir is required. Pharmacokinetic data in adult patients with severely impaired liver function (uncompensated cirrhosis), impaired synthetic liver function and the presence of portacaval anastomoses also do not indicate the need to adjust the dose of valacyclovir, however, clinical experience with this pathology is limited.
Children.
There is no data on the use of Valcicon® in children under 12 years of age.
Elderly patients.
No dose adjustment is required unless there is significant impairment of renal function. It is necessary to maintain adequate water and electrolyte balance.
VALCICON
Directions for use and doses
Inside, regardless of food intake, with water.
Treatment of herpes zoster (Herpes zoster)
Adults:
The recommended dose is 1000 mg 3 times a day for 7 days.
Treatment of infections caused by HSV (Herpes simplex)
Adults:
The recommended dose for treatment of an episode is 500 mg 2 times a day for 5 days.
In more severe cases of the onset of the disease, treatment should begin as early as possible, and its duration can be increased from 5 to 10 days. In case of relapse, treatment should continue for 3 or 5 days. For recurrent HSV, it is ideal to prescribe valacyclovir in the prodromal period or immediately after the first symptoms of the disease appear.
As an alternative for the treatment of labial herpes, the administration of valacyclovir at a dose of 2 g 2 times a day is effective. The second dose should be taken approximately 12 hours (but not earlier than 6 hours) after the first dose. When using this dosage regimen, the duration of treatment is 1 day. Therapy should be started when the earliest symptoms of herpes labialis appear: tingling, itching and/or burning.
Prevention (suppression) of recurrent infections caused by HSV
Adults:
In patients with preserved immunity, the recommended dose is 500 mg 1 time per day.
In patients with immunodeficiency, the recommended dose is 500 mg 2 times a day.
Prevention of transmission of genital herpes to a healthy partner
For infected immunocompetent individuals with relapses no more than 9 times a year, the recommended dose of valacyclovir is 500 mg once a day for a year or more, daily.
There are no data on infection prevention in other patient populations.
Prevention of cytomegalovirus (CMV) infection after transplantation
Adults and teenagers aged 12 years and older:
The recommended dose is 2 g 4 times a day, prescribed as early as possible after transplantation. The dose should be reduced depending on creatinine clearance (CC). The duration of treatment is 90 days, but in high-risk patients the course of treatment can be extended.
Special patient groups
Patients with impaired renal function:
- treatment of herpes zoster and infections caused by HSV, prevention (suppression) of relapses of infection caused by HSV, prevention of transmission of genital herpes to a healthy partner
It is recommended to reduce the dose of valacyclovir in patients with a significant decrease in renal function (see dosage regimen in Table 1). Adequate hydration should be maintained in such patients.
There is no experience with the use of valacyclovir in children with CC values less than 50 ml/min/1.73 m2.
Table 1
| Indications | CC, ml/min | Valacyclovir dose |
| Herpes zoster | 15-30 | 1 g 2 times a day |
| less than 15 | 1 g 1 time per day | |
| Treatment of infection caused by HSV (according to the regimen of 500 mg 2 times a day) | less than 15 | 500 mg 1 time per day |
| Treatment of labial herpes (according to the regimen of 2 g 2 times a day for one day) | 31-49 | 1 g twice a day |
| 15-30 | 500 mg twice a day | |
| less than 15 | 500 mg once | |
| Prevention (suppression) of recurrent infections caused by HSV: - patients with normal immunity - patients with reduced immunity – reducing the risk of transmission of genital herpes | ||
| less than 15 | 250 mg 1 time per day | |
| less than 15 | 500 mg 1 time per day | |
| less than 15 | 250 mg 1 time per day |
For patients on hemodialysis, it is recommended to use valacyclovir immediately after the end of the hemodialysis session at the same dose as in patients with CC less than 15 ml/min.
— prevention of cytomegalovirus (CMV) infection after transplantation
The regimen for valaciclovir in patients with impaired renal function should be established in accordance with Table 2.
table 2
| CC, ml/min | Valacyclovir dose |
| 75 or more | 2 g 4 times a day |
| from 50 to less than 75 | 1.5 g 4 times a day |
| from 25 to less than 50 | 1.5 g 3 times a day |
| from 10 to less than 25 | 1.5 g 2 times a day |
| less than 10 or hemodialysis* | 1.5 g 1 time per day |
* In patients undergoing hemodialysis, valacyclovir should be prescribed after the end of the hemodialysis session.
It is necessary to determine QC frequently, especially during periods when renal function changes rapidly, for example, immediately after transplantation or engraftment, and the dose of valacyclovir is adjusted in accordance with QC values.
Patients with liver dysfunction
In adult patients with mild to moderate hepatic impairment with preserved synthetic function, no dose adjustment of valacyclovir is required.
Pharmacokinetic data in adult patients with severely impaired liver function (decompensated cirrhosis), impaired synthetic liver function and the presence of portacaval anastomoses also do not indicate the need to adjust the dose of valacyclovir, however, clinical experience with this pathology is limited.
Children under 12 years of age
There is no data on the use of Valcicon® in children.
Elderly patients
No dose adjustment is required, except in patients with significant renal impairment. It is necessary to maintain adequate water and electrolyte balance.
